GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkpoint Therapeutics Inc (NAS:CKPT) » Definitions » PS Ratio

CKPT (Checkpoint Therapeutics) PS Ratio : (As of Mar. 02, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Checkpoint Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Checkpoint Therapeutics's share price is $2.86. Checkpoint Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00. Hence, Checkpoint Therapeutics's PS Ratio for today is .

The historical rank and industry rank for Checkpoint Therapeutics's PS Ratio or its related term are showing as below:

CKPT' s PS Ratio Range Over the Past 10 Years
Min: 8.48   Med: 124.24   Max: 4390
Current: 2860

During the past 9 years, Checkpoint Therapeutics's highest PS Ratio was 4390.00. The lowest was 8.48. And the median was 124.24.

CKPT's PS Ratio is ranked worse than
98.01% of 1004 companies
in the Biotechnology industry
Industry Median: 8.83 vs CKPT: 2860.00

Checkpoint Therapeutics's Revenue per Sharefor the three months ended in Sep. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00.

Warning Sign:

Checkpoint Therapeutics Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Checkpoint Therapeutics was -93.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was -70.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was -66.70% per year.

During the past 9 years, Checkpoint Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 71.80% per year. The lowest was -70.30% per year. And the median was -50.65% per year.

Back to Basics: PS Ratio


Checkpoint Therapeutics PS Ratio Historical Data

The historical data trend for Checkpoint Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkpoint Therapeutics PS Ratio Chart

Checkpoint Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only 35.54 138.74 888.57 232.27 458.00

Checkpoint Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 113.33 458.00 512.50 716.67 -

Competitive Comparison of Checkpoint Therapeutics's PS Ratio

For the Biotechnology subindustry, Checkpoint Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Checkpoint Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Checkpoint Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Checkpoint Therapeutics's PS Ratio falls into.



Checkpoint Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Checkpoint Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=2.86/0.001
=

Checkpoint Therapeutics's Share Price of today is $2.86.
Checkpoint Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Checkpoint Therapeutics  (NAS:CKPT) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Checkpoint Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Checkpoint Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Checkpoint Therapeutics Business Description

Traded in Other Exchanges
Address
95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Executives
Oliviero James F Iii director, officer: CEO, President and Director C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
William Garrett Gray officer: See Remarks 2 GANSEVOORT STREET,, 9TH FLOOR, NEW YORK NY 10014
Fortress Biotech, Inc. 10 percent owner 1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Michael S Weiss director 750 LEXINGTON AVE, NEW YORK NY 10022
Neil Herskowitz director 2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Christian Bechon director C/O LFB, 3, AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91940
Barry M Salzman director 464 COMMON STREET, SUITE 301, BELMONT MA 02478
Scott Boilen director 2 SKYLINE DRIVE, HAWTHORNE NY 10532
Rosenwald Lindsay A Md director 375 PARK AVE, NEW YORK NY 10152
David J Horin officer: Interim CFO 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020

Checkpoint Therapeutics Headlines

From GuruFocus